Welcome to our dedicated page for Wave Life Sciences Ltd. SEC filings (Ticker: WVE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Wave Life Sciences Ltd.'s stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Wave Life Sciences Ltd.'s regulatory disclosures and financial reporting.
RA Capital Management and related parties report owning 34,225,506 ordinary shares of Wave Life Sciences Ltd., representing 17.1% of the company’s ordinary shares outstanding. Their holdings include shares held by RA Capital Healthcare Fund, pre-funded warrants that are immediately exercisable, and options held by Peter Kolchinsky for RA Capital’s benefit.
The group reports shared voting and dispositive power over these securities and disclaims beneficial ownership beyond Section 13(d) reporting purposes. The amendment also notes that Wave Life Sciences Ltd. entered into an Implementation Agreement for a Singapore-law Scheme of Arrangement to redomicile into a new Delaware corporation, Wave Life Sciences, Inc., with a one-for-one share exchange, subject to shareholder and Singapore court approval.
Wave Life Sciences Ltd. is asking shareholders to approve a Scheme of Arrangement to redomicile the parent from Singapore to a newly formed Delaware corporation, Wave Life Sciences, Inc. under an Implementation Agreement dated April 15, 2026. Under the Scheme, each Wave-Singapore ordinary share will be exchanged one-for-one for Wave-Delaware common stock, which the company intends to list on Nasdaq under the symbol WVE. The Scheme requires shareholder approval (a majority in number and at least 75% of votes cast by value) and sanction by the Singapore High Court; if approved and conditions satisfied, the court order will be lodged with ACRA and the Scheme will become effective. The board unanimously recommends a vote FOR the Wave Redomiciliation Proposal. The proxy statement discusses differences in shareholder rights under Delaware law, potential tax and stamp duty considerations (including a Singapore stamp duty rate of 0.2%), and expected U.S. GAAP accounting as a common-control reorganization.
Wave Life Sciences Ltd. plans to move its parent company domicile from Singapore to Delaware through a court-approved redomiciliation. Under a Singapore law scheme of arrangement, each existing Wave-Singapore ordinary share will be exchanged on a one-for-one basis for common stock of a new Delaware parent, Wave Life Sciences, Inc.
The new Delaware parent is expected to become the group’s ultimate holding company in mid-2026, subject to shareholder and Singapore High Court approvals, while continuing to operate the business substantially as before. The stock will keep trading on the Nasdaq Global Market under the symbol WVE, with reporting in U.S. dollars under U.S. GAAP, and the redomiciliation is expected to be tax-free to U.S. shareholders.
RA Capital and affiliates report a larger stake in Wave Life Sciences Ltd., now beneficially owning 34,225,506 ordinary shares, or 17.5% of the company’s outstanding shares. The ownership is reported across RA Capital Management, its healthcare fund, and managers Peter Kolchinsky and Rajeev Shah.
The amendment details recent open-market purchases by RA Capital Healthcare Fund, including multi-million share buys on March 26, 27, and 30, 2026 at weighted-average prices between $6.06 and $6.50 per share, funded with the fund’s working capital. Certain shares are issuable upon exercise of pre-funded warrants and stock options.
Wave Life Sciences Ltd. reported significant open-market buying by entities associated with RA Capital. RA Capital Healthcare Fund LP, advised by RA Capital Management, L.P., purchased a total of 8,772,496 ordinary shares in open-market transactions between March 26 and March 30, 2026 at prices around $6.06–$6.50 per share. Following these purchases, the Fund’s indirect holdings reached 26,975,505 ordinary shares, with an additional 28,815 shares linked to previously reported RSU awards held by Dr. Peter Kolchinsky for the benefit of the Fund. The Adviser, its general partner, the Fund, Dr. Kolchinsky and Mr. Rajeev Shah each disclaim beneficial ownership of the reported securities except to the extent of their pecuniary interest.
Wave Life Sciences Ltd. reported that entities associated with director Ken Takanashi converted 3,901,348 Series A preferred shares into the same number of ordinary shares on a one-for-one basis. This was a non-cash derivative conversion, not an open-market purchase or sale.
After the conversion, those entities collectively held 9,606,408 ordinary shares indirectly, while Takanashi also held 23,943 ordinary shares directly. Footnotes state the shares are held by SNBL USA, Ltd. and Shin Nippon Biomedical Laboratories, Ltd., and Takanashi disclaims beneficial ownership except to the extent of his pecuniary interest.
Wave Life Sciences reported positive interim Phase 1 data from its INLIGHT trial of WVE-007, an investigational INHBE GalNAc-siRNA for people living with overweight or obesity. After six months, a single 240 mg dose produced placebo-adjusted reductions in visceral fat of -14%, total fat of -5%, waist circumference of -3%, and body weight of -1%, while lean mass increased by +2%. WVE-007 showed durable, dose-dependent suppression of serum Activin E for at least seven months, supporting the potential for once or twice-yearly dosing, and was generally safe and well tolerated up to 600 mg, with only mild or moderate adverse events.
Wave Life Sciences Ltd. officer Francis Chris reported option exercises and share sales in Wave Life Sciences ordinary shares. On February 26, 2026, he exercised two share options for 17,900 and 15,294 shares at exercise prices of $3.87 and $4.75 per share, respectively, receiving the corresponding ordinary shares. He then sold 17,900 shares at a weighted-average price of $15.094 per share and 15,294 shares at $15.00 per share in open-market transactions. The filing notes these transactions were carried out under a pre-established Rule 10b5‑1 trading plan, and after the reported trades he held 61,867 ordinary shares directly.
Wave Life Sciences Ltd. provides an annual overview of its business, pipeline and risks as a clinical-stage RNA medicines company. The company focuses on obesity, alpha-1 antitrypsin deficiency (AATD), PNPLA3 I148M liver disease, Duchenne muscular dystrophy and Huntington’s disease using its PRISM chemistry platform.
Lead programs include WVE-007 for obesity, WVE-006 for AATD and WVE-008 for PNPLA3 I148M liver disease, alongside WVE-N531 for DMD and WVE-003 for allele-selective Huntington’s disease. As of June 30, 2025, the aggregate market value of non-affiliate shares was $851,013,538, and ordinary shares outstanding were 188,254,954 as of February 19, 2026.
Wave Life Sciences reported much higher cash and a larger loss for 2025 while outlining ambitious RNA programs in obesity, liver and lung disease. Cash and cash equivalents rose to $602.1 million as of December 31, 2025, giving an expected cash runway into Q3 2028.
Full-year 2025 revenue was $42.7 million, down from $108.3 million in 2024, as collaboration revenue declined. Research and development expenses increased to $182.8 million and general and administrative to $75.3 million, driving a net loss of $204.4 million versus a $97.0 million loss in 2024.
The company highlighted WVE-007 for obesity, where a single dose showed fat loss similar to GLP‑1 drugs at three months while preserving lean mass, with data updates and a Phase 2a multidose trial planned in 2026. It also advanced WVE‑006 for alpha‑1 antitrypsin deficiency, achieving total AAT levels above 11 micromolar and dynamic increases during acute phase responses, and plans a 2026 clinical trial application for WVE‑008 in PNPLA3 I148M liver disease.